Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Searle_Pharmaceuticals
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:2001
gptkb:FDA |
| gptkbp:brand |
gptkb:Focalin
|
| gptkbp:class |
CNS stimulant
|
| gptkbp:clinical_trial |
Phase IV
|
| gptkbp:contraindication |
gptkb:sneaker
heart problems hyperthyroidism |
| gptkbp:dosage_form |
gptkb:beer
gptkb:tablet |
| gptkbp:duration |
varies by patient
|
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
racemic mixture
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dexmethylphenidate
|
| gptkbp:ingredients |
C14 H19 N O2
|
| gptkbp:interacts_with |
antidepressants
MAO inhibitors antihypertensives |
| gptkbp:is_available_in |
various strengths
|
| gptkbp:is_available_on |
extended-release formulation
|
| gptkbp:is_monitored_by |
cardiovascular status
growth in children |
| gptkbp:is_used_for |
treatment of ADHD
|
| gptkbp:lifespan |
2.2 hours
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:metabolism |
liver
|
| gptkbp:pharmacokinetics |
oral bioavailability
dopamine reuptake inhibitor norepinephrine reuptake inhibitor peak plasma concentration time to peak concentration |
| gptkbp:related_to |
gptkb:drug
|
| gptkbp:requires |
gptkb:theorem
|
| gptkbp:side_effect |
anxiety
nausea allergic reactions seizures decreased appetite insomnia cardiovascular events dry mouth improved academic performance improved focus tics psychiatric symptoms reduced impulsivity better social interactions enhanced task performance |
| gptkbp:type_of |
2205-53-2
|